Vinceti M, Balboni E, Rothman KJ, Teggi S, Bellino S, Pezzotti P, Ferrari F, Orsini N, Filippini T. Substantial impact of mobility restrictions on reducing COVID-19 incidence in Italy in 2020. J Travel Med. 2022 Sep;29(6):taac081. doi: 10.1093/jtm/taac081
Groenwold RH, Klungel OH, Altman DJ, van der Graaf Y, Hoes AW, Moons KG, Rivero E, Fortuny J, PROTECT WP2. Adjustment for continuous confounders: an example of how to prevent residual confounding. Can Med Assoc J. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592
Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Assoc J. 2011 Apr 1;183(7):E411-9.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Mirabelli MC, Zock JP, Bircher AJ, Jarvis D, Keidel D, Kromhout H, Norbäck D, Olivieri M, Plana E. Metalworking exposures and persistent skin symptoms in the ECRHS II and SAPALDIA 2 cohorts. Contact Dermatitis. 2009 May;60(5):256-63.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.